Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail
Spruce Biosciences Announces Topline Results from CAHmelia-203
Spruce Reports Full Year 2023 Financial Results and Provides Corporate Updates
Spruce Biosciences to Present at the Oppenheimer 34th Annual Conference
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
The US Patent Trial and Appeal Board will take a closer look at two patents covering Spruce Biosciences’ experimental treatment for an adrenal disorder, reversing recent decisions denying post-grant review.
Spruce Biosciences Reports Third Quarter 2023 Financial Results